Regeneron Pharmaceuticals Inc.
REGN | NASDAQ
$968.46
+$40.57 (+4.37%)
Nov 2, 2026, 12:04 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | 14.34B | 14.2B | 13.12B | 12.17B | 16.07B | 8.5B |
Cost of Revenue | 2.1B | 1.97B | 2.24B | 1.71B | 2.72B | 1.36B |
Gross Profit | 12.24B | 12.23B | 10.87B | 10.47B | 13.35B | 7.14B |
Operating Income | 3.58B | 3.99B | 4.35B | 5.39B | 8.95B | 3.58B |
Interest Income | 716.8M | 711.4M | 495.9M | 160.1M | n/a | n/a |
Pretax Income | 5.23B | 4.78B | 4.2B | 4.86B | 9.33B | 3.81B |
Net Income | 4.5B | 4.41B | 3.95B | 4.34B | 8.08B | 3.51B |
Selling & General & Admin | 2.7B | 2.95B | 2.54B | 2.12B | 1.82B | 1.35B |
Research & Development | 5.85B | 5.23B | 3.99B | 3.06B | 2.62B | 2.5B |
Other Expenses | 114.1M | 53.4M | -2.1M | -89.9M | -45.6M | -280.4M |
Operating Expenses | 8.66B | 8.24B | 6.52B | 5.08B | 4.4B | 3.56B |
Interest Expense | 43.8M | 55.2M | 73M | 59.4M | 57.3M | 56.9M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 10.77B | 10.21B | 8.77B | 6.79B | 7.12B | 4.92B |
Income Tax Expense | 725.8M | 367.3M | 245.7M | 520.4M | 1.25B | 297.2M |
Shares Outstanding (Basic) | 104.6M | 107.9M | 106.7M | 107.1M | 105.7M | 107.6M |
Shares Outstanding (Diluted) | 108.6M | 115.1M | 113.7M | 113.5M | 112.2M | 115.1M |
EPS (Basic) | 43.07 | 40.90 | 37.05 | 40.51 | 76.40 | 32.65 |
EPS (Diluted) | 41.48 | 38.34 | 34.77 | 38.22 | 71.97 | 30.52 |
EBITDA | 5.82B | 5.32B | 4.69B | 5.26B | 9.67B | 4.1B |
EBIT | 5.27B | 4.84B | 4.27B | 4.92B | 9.38B | 3.87B |
Depreciation & Amortization | 543.7M | 482.9M | 421M | 341.4M | 286.2M | 235.9M |
Add to Watchlist
Select watchlists to add or remove REGN